We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals
IRWD

152 hedge funds and large institutions have $1.76B invested in Ironwood Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 26 increasing their positions, 96 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $8.76M | Put options by funds: $6.2M

6% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 32

3% less funds holding

Funds holding: 156 → 152 (-4)

16% less capital invested

Capital invested by funds: $2.09B → $1.76B (-$330M)

16.03% less ownership

Funds ownership: 119.69% → 103.66% (-16%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

73% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 96

Holders
152
Holders Change
-4
Holders Change %
-2.56%
% of All Funds
3.3%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
30
Increased
26
Reduced
96
Closed
32
Calls
$8.76M
Puts
$6.2M
Net Calls
+$2.56M
Net Calls Change
-$13.2M

Top Buyers

1
UBS AM
UBS AM
Illinois
+$19M
2
PCM
Peregrine Capital Management
Minnesota
+$13.8M
3
N
Nuveen
North Carolina
+$10.4M
4
BCPEMI
Bain Capital Public Equity Management II
Massachusetts
+$9.04M
5
SCM
Sarissa Capital Management
Connecticut
+$7.98M

Top Sellers

1
BM
Bridger Management
New York
-$56.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$45.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$40.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$25M
5
BlackRock
BlackRock
New York
-$18.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
151
Parallel Advisors
California
$1K +$1.21K +108 New
GT
152
Glenmede Trust
Pennsylvania
$22 -$4.4K -393 -16%
BM
153
Bridger Management
New York
– -$56.6M -4,993,179 Closed
BCPEM
154
Bain Capital Public Equity Management
Massachusetts
– -$5.51M -486,672 Closed
Renaissance Technologies
155
Renaissance Technologies
New York
– -$4.84M -426,799 Closed
HI
156
HBK Investments
Texas
– -$3.01M -268,769 Closed
EGM
157
Engineers Gate Manager
New York
– -$3.04M -268,194 Closed
EP
158
Eversept Partners
New York
– -$2.65M -233,667 Closed
Squarepoint
159
Squarepoint
New York
– -$2.55M -225,323 Closed
UONDDL
160
University of Notre Dame du Lac
Indiana
– -$2.51M -221,500 Closed
LCM
161
Laurion Capital Management
New York
– -$1.75M -153,954 Closed
AI
162
Atom Investors
Texas
– -$1.72M -152,073 Closed
MIM
163
Monashee Investment Management
Massachusetts
– -$1.35M -119,400 Closed
Man Group
164
Man Group
United Kingdom
– -$1.21M -107,015 Closed
LA
165
Linden Advisors
New York
– -$970K -85,579 Closed
TEE
166
Tibra Equities Europe
United Kingdom
– -$920K -81,192 Closed
PP
167
Paloma Partners
Connecticut
– -$864K -76,219 Closed
OAM
168
Oxford Asset Management
United Kingdom
– -$742K -65,502 Closed
QIM
169
Quantitative Investment Management
Virginia
– -$687K -60,655 Closed
TD Asset Management
170
TD Asset Management
Ontario, Canada
– -$636K -56,138 Closed
ACM
171
AlphaCrest Capital Management
New York
– -$325K -28,656 Closed
PA
172
Perennial Advisors
New York
– -$243K -21,432 Closed
HT
173
HAP Trading
New York
– -$208K -18,384 Closed
Verition Fund Management
174
Verition Fund Management
Connecticut
– -$157K -13,854 Closed
Invesco
175
Invesco
Georgia
– -$156K -13,792 Closed
4 5 6
7
8

IRWD Hedge Fund Activity: Q2 2019 in Review

152 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2019, worth a combined $1.76B — down 16% from $2.09B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of IRWD and 30 opened new positions — a net loss of 2 holders — while 96 trimmed existing stakes and 26 added.

The largest buyer was UBS AM, adding an estimated $19M. The largest seller was Bridger Management, exiting entirely with an estimated $56.6M sold.

  • 152 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2019, down from 156 in Q1 2019.
  • Funds reported $1.76B of Ironwood Pharmaceuticals stock for Q2 2019, down 16% quarter-over-quarter.
  • 30 funds opened new Ironwood Pharmaceuticals positions in Q2 2019 and 32 closed out, a net change of -2 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q2 2019 was UBS AM, an estimated $19M added.
  • The largest Ironwood Pharmaceuticals seller in Q2 2019 was Bridger Management, an estimated $56.6M sold.

Based on aggregated 13F filings for Q2 2019.